Various Wall Street firms see nearly $1,000 per share within 12 months. And I will candidly admit -- that is a sober assessment. The ramp of supply, for two drugs they likely can sell unlimited amounts of -- at pretty outrageous prices. . . seems solid. In any event, here's a bit, from last week's news, as well:
. . .“Now that we’re four months into the year, we have greater visibility into that, into these nodes of capacity and feel more confident,” Eli Lilly CFO Anat Ashkenazi told investors during an earnings call Tuesday.
She noted that Eli Lilly has several manufacturing sites either “ramping up or under construction,” including two locations in North Carolina, two in Indiana, one in Ireland and one in Germany, along with a seventh site the company recently acquired from Nexus Pharmaceuticals.
Eli Lilly said demand for Mounjaro and Zepbound — treatments known as incretin drugs, which mimic hormones produced in the gut to suppress a person’s appetite and regulate their blood sugar — outpaced increases in supply during the quarter. And the company expects supply to remain “quite tight” in the near- to mid-term amid continued demand for those drugs, Ashkenazi said.
But Eli Lilly expects the most significant production increases expected in the second half of the year, she noted.
“Our top priority is making more product, and we’re doing everything we can to do that,” Eli Lilly CEO David Ricks said in an interview Tuesday on CNBC’s “Squawk Box.” “We’re ramping that aggressively. But it’s capital intensive, it’s technically complex and highly regulated. . . .”
Now you know -- but I'd suggest that the company ought to split the stock about 8-for-one, to (simple math!) get the NYSE per share price down below ~$100 a share, and thus let more moms and pops get in on it, with their IRA money. Onward to a sunny and relaxing Spring weekend, in celebration of moms everywhere!
नमस्ते
1 comment:
Thrice -- at 4:46 am to 4:49 am... hey you!
Post a Comment